RSS feed: news [?]

Home » News » Lubrizol Invests $60 Million to Expand Particle Sciences, Vesta and Other Facilities in 2017

Lubrizol LifeSciences continues to invest in its key capabilities. During this latest phase, a $60 million investment will focus on new product solutions, capacity expansion and additional cGMP manufacturing. These investments will strengthen the excipients, polymers, drug formulation and manufacturing, and medical device contract manufacturing capabilities at their global facilities.

LifeSciences will add commercial drug product manufacturing at its Particle Sciences facility in Bethlehem, PA. Leveraging the company's knowledge in complex formulations and production, the facility will be adjacent to the existing development and clinical trial manufacturing site, offering customers a seamless flow from development through manufacturing. This new space, which will be operational Q4 2017, will accommodate both sterile and non-sterile products, highly potent compounds, and organic solvent processing.    

Additionally, LifeSciences is investing to expand its global facilities for excipients, polymers and contract manufacturing; with a focus on quality and efficiency. This capital investment will impact multiple sites to increase in-house engineering capacity across the LifeSciences portfolio of medical and pharmaceutical applications. This includes new investments in design, manufacturing and sterilization technologies for the production of interventional catheters and long-term implantable devices, an area of strategic importance to the medical device segment.

All rights reserved. No information from the web site may be reproduced without the permission of the magazine's editorial board.

© Eurasian chemical market, 2005-2023